BLAINJECTIONINJECTABLE
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYLTEZO is an adalimumab biosimilar (ADALIMUMAB-ADBM) developed by Boehringer Ingelheim, approved in 2017. It is a monoclonal antibody TNF inhibitor used to treat rheumatoid arthritis and other inflammatory conditions. The drug works by binding to and neutralizing tumor necrosis factor (TNF), a key driver of inflammation in autoimmune diseases.
Peak
Peak-stage biosimilar facing moderate competitive pressure (30), suggesting stable but mature commercial operations with potential for specialty care and payer negotiation expertise.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CYLTEZO offers exposure to biosimilar commercialization, payer negotiation, and specialty immunology markets in a peak-stage product. Career value lies in learning biosimilar positioning, formulary management, and competition against branded TNF inhibitors and newer-generation biologics.
Brand ManagerMedical Science Liaison
Worked on CYLTEZO at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.